Article Details
Retrieved on: 2024-07-02 18:38:49
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The agency's labeling for the drug, which Lilly will sell as Kisunla, recommends starting treatment in people with either mild cognitive impairment or ...
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here